Beam Therapeutics Inc. – NASDAQ:BEAM

Add to watchlist

$16.4

-10.19

-38.32%

Market closed

Open in 3 days

-1.08%

month

-1.08%

quarter

-8.56%

year

Market Cap	2.37B
Enterprise value	2.07B

P/E	-7.37
EV/Sales	34.07
EV/EBITDA	-8.10
Price/Sales	34.95
Price/Book	2.90
PEG ratio	-0.25
EPS	-1.74

Revenue	360.91M
EBITDA	-177.79M
Income	-134.73M
Revenue Q/Q	-69.39%
Revenue Y/Y	370.57%

Profit margin	-474.54%
Oper. margin	-555.61%
Gross margin	0%
EBIT margin	-555.61%
EBITDA margin	-49.26%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Beam Therapeutics Stock Forecast

M Q Y

Last Year

$55

Potential upside: 235.36%

Analysts Price target
Financials & Ratios estimates

Beam Therapeutics Inc. (NASDAQ:BEAM): Profit margin
Jun 2023	20.11M	-82.77M	-411.49%
Sep 2023	17.19M	-96.08M	-558.88%
Dec 2023	316.19M	142.79M	45.16%
Mar 2024	7.41M	-98.66M	-1331.57%

Beam Therapeutics Inc. (NASDAQ:BEAM): Payout ratio
Payout ratio	0%

Beam Therapeutics Inc. (NASDAQ:BEAM): Dividend Yield
2019	1.32%
2020
2021
2022
2023

Beam Therapeutics Inc. (NASDAQ:BEAM): Debt to assets
Jun 2023	1353887000	542.24M	40.05%
Sep 2023	1290534000	511.59M	39.64%
Dec 2023	1459714000	478.38M	32.77%
Mar 2024	1359796000	446.30M	32.82%

Beam Therapeutics Inc. (NASDAQ:BEAM): Cash Flow
Jun 2023	-84.66M	-41.48M	107.54M
Sep 2023	-89.78M	-10.23M	36.77M
Dec 2023	135.07M	98.09M	33.71M
Mar 2024	-99.74M	-53.46M	2.89M

Beam Therapeutics alternative data

Beam Therapeutics Inc. (NASDAQ:BEAM): Employee count
Aug 2023	523
Sep 2023	532
Oct 2023	532
Nov 2023	532
Dec 2023	439
Jan 2024	439
Feb 2024	439
Mar 2024	436
Apr 2024	436
May 2024	436
Jun 2024	346
Jul 2024	346

Beam Therapeutics
Hedge Funds Holdings Q3 2022

70.98% -7.50%

of BEAM is owned by hedge funds

199 +8

hedge funds hold BEAM stock

49.83M -4.08M

shares is hold by hedge funds

BEAM hedge funds holdings changes

Beam Therapeutics
Insider Trading

Beam Therapeutics Inc. (NASDAQ:BEAM): Insider trades (number of shares)
Period	Buy	Sel
Jun 2024	0	60000
Jul 2024	0	1250
Sep 2024	0	60000
Oct 2024	0	51784
Nov 2024	0	51110

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	17 Dec 2024	CIARAMELLA GIUSEPPE officer: President	Common Stock	53,500	$0.67	$35,845
Option	17 Dec 2024	CIARAMELLA GIUSEPPE officer: President	Stock Option (Right to Buy)	53,500	$0.67	$35,845
Sale	6 Nov 2024	CIARAMELLA GIUSEPPE officer: President	Common Stock	51,110	$26.36	$1,347,055
Option	14 Oct 2024	CIARAMELLA GIUSEPPE officer: President	Common Stock	1,457	$7.22	$10,520
Option	14 Oct 2024	CIARAMELLA GIUSEPPE officer: President	Common Stock	12,979	$4.22	$54,771
Option	14 Oct 2024	CIARAMELLA GIUSEPPE officer: President	Common Stock	27,318	$0.67	$18,303
Sale	14 Oct 2024	CIARAMELLA GIUSEPPE officer: President	Common Stock	51,110	$26.27	$1,342,762
Option	14 Oct 2024	CIARAMELLA GIUSEPPE officer: President	Stock Option (Right to Buy)	41,754	$4.04	$168,561
Sale	1 Oct 2024	BELLON CHRISTINE officer: Chief Legal Officer officer: Chief Legal Officer	Common Stock	385	$23.48	$9,039
Sale	1 Oct 2024	CAVANAGH BETHANY J officer: SVP, Finance and Treasurer officer: SVP, Finance and Treas..	Common Stock	289	$23.48	$6,785

BEAM insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application NANOMATERIALS COMPRISING A BIODEGRADABLE FEATURE Filling date: 19 Jan 2022 Issue date: 11 Aug 2022	19 Jan 2022	11 Aug 2022
Application	Application NANOMATERIALS Filling date: 19 Jan 2022 Issue date: 11 Aug 2022	19 Jan 2022	11 Aug 2022
Application	Application ADENOSINE DEAMINASE BASE EDITORS AND METHODS OF USING SAME TO MODIFY A NUCLEOBASE IN A TARGET SEQUENCE Filling date: 13 Feb 2020 Issue date: 2 Jun 2022	13 Feb 2020	2 Jun 2022
Application	Application SYSTEMS AND METHODS FOR IMPLEMENTED MIXED REALITY IN LABORATORY AUTOMATION Filling date: 3 Feb 2020 Issue date: 5 May 2022	3 Feb 2020	5 May 2022
Application	Application NUCLEOBASE EDITORS HAVING REDUCED OFF-TARGET DEAMINATION AND METHODS OF USING SAME TO MODIFY A NUCLEOBASE TARGET SEQUENCE Filling date: 31 Jan 2020 Issue date: 5 May 2022	31 Jan 2020	5 May 2022
Application	Application MODIFIED IMMUNE CELLS HAVING ENHANCED ANTI-NEOPLASIA ACTIVITY AND IMMUNOSUPPRESSION RESISTANCE Filling date: 16 Jan 2020 Issue date: 5 May 2022	16 Jan 2020	5 May 2022
Application	Application COMPOSITIONS AND METHODS FOR TREATING GLYCOGEN STORAGE DISEASE TYPE 1A Filling date: 13 Feb 2020 Issue date: 28 Apr 2022	13 Feb 2020	28 Apr 2022
Application	Application Compositions and Methods for Improving Base Editing Filling date: 7 Sep 2019 Issue date: 28 Apr 2022	7 Sep 2019	28 Apr 2022
Application	Application SPLICE ACCEPTOR SITE DISRUPTION OF A DISEASE-ASSOCIATED GENE USING ADENOSINE DEAMINASE BASE EDITORS, INCLUDING FOR THE TREATMENT OF GENETIC DISEASE Filling date: 13 Feb 2020 Issue date: 31 Mar 2022	13 Feb 2020	31 Mar 2022
Application	Application NUCLEOBASE EDITORS HAVING REDUCED NON-TARGET DEAMINATION AND ASSAYS FOR CHARACTERIZING NUCLEOBASE EDITORS Filling date: 31 Jan 2020 Issue date: 31 Mar 2022	31 Jan 2020	31 Mar 2022

Beam Therapeutics
Earnings Call Transcripts

Quarter	Transcript
Q3 2013 31 Oct 2013	Q3 2013 Earnings Call Transcript
Q2 2013 8 Aug 2013	Q2 2013 Earnings Call Transcript
Q1 2013 2 May 2013	Q1 2013 Earnings Call Transcript
Q4 2012 1 Feb 2013	Q4 2012 Earnings Call Transcript

BEAM earnings call transcripts

Beam Therapeutics
Executives

Insider	Age	Compensation
Mr. John M. Evans M.B.A. (1978) Chief Executive Officer & Director	47	$906,770
Dr. Giuseppe Ciaramella Ph.D. (1969) Pres & Chief Scientific Officer	56	$746,240
Ms. Terry-Ann Burrell M.B.A. (1977) Chief Financial Officer & Treasurer	48	$683,750

Beam Therapeutics
Latest News

Monday, 23 December 2024
10:40	5 Biotech Breakthrough Stocks to Watch in 2025	zacks.com
Monday, 9 December 2024
09:25	Beam Therapeutics Appoints Sravan Emany as New CFO, Shares Up	zacks.com
Sunday, 8 December 2024
13:45	Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting	globenewswire.com
Saturday, 7 December 2024
11:30	Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting	globenewswire.com
Friday, 6 December 2024
07:00	Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer	globenewswire.com
Thursday, 5 December 2024
12:36	Why Is Beam Therapeutics (BEAM) Down 2.3% Since Last Earnings Report?	zacks.com
Wednesday, 4 December 2024
07:00	Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader	globenewswire.com
Tuesday, 12 November 2024
16:01	Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference	globenewswire.com
Thursday, 7 November 2024
14:25	Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch	seekingalpha.com
Wednesday, 6 November 2024
12:41	Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates	zacks.com
Tuesday, 5 November 2024
11:54	Beam Therapeutics Inc. (BEAM) Q3 2024 Earnings Call Transcript	seekingalpha.com
08:42	Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates	zacks.com
06:30	Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs	globenewswire.com
Tuesday, 29 October 2024
06:30	Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting	globenewswire.com
Thursday, 5 September 2024
12:36	Why Is Beam Therapeutics (BEAM) Down 1.6% Since Last Earnings Report?	zacks.com
Friday, 9 August 2024
10:19	3 Gene Editing Stocks with Potential to Transform Medicine	investorplace.com
Wednesday, 7 August 2024
11:52	Beam Therapeutics (BEAM) Q2 Earnings Beat, Revenues Miss	zacks.com
Tuesday, 6 August 2024
08:46	Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates	zacks.com
06:30	Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results	globenewswire.com
Friday, 26 July 2024
08:45	Beam Therapeutics (BEAM) Soars 7.9%: Is Further Upside Left in the Stock?	zacks.com
Wednesday, 24 July 2024
08:23	Trade of the Day: Buy Beam Therapeutics Call Options as BEAM Stock Heads to $40	investorplace.com
Monday, 22 July 2024
16:45	3 Gene Editing Stocks Shaping the Future of Medicine	investorplace.com
Tuesday, 16 July 2024
11:16	Beam Therapeutics' (BEAM) CFO to Step Down, Stock Declines	zacks.com
Thursday, 11 July 2024
14:01	Here's Why You Should Invest in Beam Therapeutics (BEAM) Now	zacks.com
Tuesday, 9 July 2024
13:01	Beam Therapeutics (BEAM) Upgraded to Buy: What Does It Mean for the Stock?	zacks.com
07:00	The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024	investorplace.com
06:25	3 Stocks With the Potential to 10X Your Money	investorplace.com
Thursday, 4 July 2024
14:13	FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals	investorplace.com
Wednesday, 3 July 2024
09:12	3 Stocks This Amazon-Backed AI Says Will Turn $1K into $1M by 2030	investorplace.com
Thursday, 27 June 2024
22:02	You've Been Warned! 3 Gene Editing Stocks to Buy Now or Regret Forever.	investorplace.com

Ideas & Opinions

Seeking Alpha 20 Jun 2025

Beam Therapeutics: Progress Of BEAM-101 Presses Forward With H2 2025 Data Releases
Seeking Alpha 5 May 2025

CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts
Seeking Alpha 16 Jan 2025

CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers
Seeking Alpha 30 Apr 2024

Invest In A Revolutionary Gene Therapy With CRISPR Therapeutics
Seeking Alpha 30 Nov 2023

CRISPR Gene Editing: Beam Therapeutics
Seeking Alpha 10 Nov 2023

Beam Therapeutics: Sale Of Rights To Verve's In Vivo Candidates An Odd Decision
Seeking Alpha 22 Oct 2023

Beam: Opportunity Based On SCD Data Readout In 2024
Seeking Alpha 20 May 2023

Beam Therapeutics: Base Editing Leader With Major Catalyst Next Year
Seeking Alpha 23 Feb 2023

Beam Therapeutics: An Upgraded View
Seeking Alpha 8 Feb 2023

Sana Biotechnology: Time And Cash Burn Are The Enemies

Frequently Asked Questions (FAQ)

What's the price of Beam Therapeutics stock today?

One share of Beam Therapeutics stock can currently be purchased for approximately $16.4.
When is Beam Therapeutics's next earnings date?

Unfortunately, Beam Therapeutics's (BEAM) next earnings date is currently unknown.
Does Beam Therapeutics pay dividends?

No, Beam Therapeutics does not pay dividends.
How much money does Beam Therapeutics make?

Beam Therapeutics has a market capitalization of 2.37B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 520.01% to 377.71M US dollars.
What is Beam Therapeutics's stock symbol?

Beam Therapeutics Inc. is traded on the NASDAQ under the ticker symbol "BEAM".
What is Beam Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Beam Therapeutics?

Shares of Beam Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Beam Therapeutics's key executives?
Beam Therapeutics's management team includes the following people:
- Mr. John M. Evans M.B.A. Chief Executive Officer & Director(age: 47, pay: $906,770)
- Dr. Giuseppe Ciaramella Ph.D. Pres & Chief Scientific Officer(age: 56, pay: $746,240)
- Ms. Terry-Ann Burrell M.B.A. Chief Financial Officer & Treasurer(age: 48, pay: $683,750)
How many employees does Beam Therapeutics have?

As Jul 2024, Beam Therapeutics employs 346 workers, which is 21% less then previous quarter.
When Beam Therapeutics went public?

Beam Therapeutics Inc. is publicly traded company for more then 5 years since IPO on 6 Feb 2020.
What is Beam Therapeutics's official website?

The official website for Beam Therapeutics is beamtx.com.
Where are Beam Therapeutics's headquarters?

Beam Therapeutics is headquartered at 238 Main Street, Cambridge, MA.
How can i contact Beam Therapeutics?

Beam Therapeutics's mailing address is 238 Main Street, Cambridge, MA and company can be reached via phone at 857 327 8775.
What is Beam Therapeutics stock forecast & price target?

Based on 3 Wall Street analysts` predicted price targets for Beam Therapeutics in the last 12 months, the avarage price target is $55. The average price target represents a 235.36% change from the last price of $16.4.

Beam Therapeutics Inc.

beamtx.com

Exchange:

NASDAQ

Full time employees:

472

Industry:

Biotechnology

Sector:

Healthcare

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

857 327 8775

238 Main Street
Cambridge, MA 02142

CIK: 0001745999
ISIN: US07373V1052
CUSIP: 07373V105